Peter Olson
About
Peter Olson is from San Diego, California, United States. Peter is currently Chief Scientific Officer at Iambic Therapeutics, located in San Diego, California, United States. In Peter's previous role as a Vice President, Research at Bristol Myers Squibb, Peter worked in San Diego, California, United States until Dec 2024. Prior to joining Bristol Myers Squibb, Peter was a Vice President, Research at Mirati Therapeutics and held the position of Vice President, Research at San Diego, California, United States. Prior to that, Peter was a Executive Director of Research at Mirati Therapeutics, based in San Diego, California, United States from Jan 2022 to Jan 2024. Peter started working as Senior Director of Research at Mirati Therapeutics in Greater San Diego Area in May 2019. From Oct 2015 to May 2019, Peter was Director of Research at Mirati Therapeutics, based in Greater San Diego Area. Prior to that, Peter was a Senior Principal Scientist at Pfizer, based in La Jolla, CA from Sep 2014 to Oct 2015. Peter started working as Principal Scientist at Pfizer Pharmaceuticals in La Jolla, CA in Oct 2009.
Go to finalscout.com and type Peter Olson's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Peter Olson's current jobs
Peter Olson's past jobs
*Directed in vitro and in vivo drug discovery pharmacology and translational research lab *Led biology-side drug discovery projects from target validation to Phase I *Oversaw highly productive translational team that used genetic and pharmacologic strategies to elucidate drug MOA, identify clinically-tractable biomarkers of intrinsic and acquired resistance, and identify efficacious combinations *Led clinical translational sciences for multiple clinical-stage programs with oncogenic driver, synthetic lethal and immune-based mechanisms of action
*Directed translational research for clinical program. Responsible for generating patient selection hypotheses, identification of clinically useful biomarkers, elucidating mechanisms of resistance to targeted therapies and identifying more efficacious and durable combination strategies. *Research Project Lead for a drug discovery oncology program. Responsible for the biology of the program on a multi-disciplinary team including identification of cell based biomarkers, understanding mechanism of action, identifying patient populations of interest and program strategy. *Target identification / validation. Using a variety of bioinformatics and functional approaches to validate new target hypotheses and find the next generation of cancer drugs.
*Directed translational research for clinical programs *Research Project Lead for drug discovery program *Led in vivo pharmacology lab *Led target identification / validation lab
Laboratory of Douglas Hanahan Studied microRNAs in cancer, angiogenesis, pancreatic cancer, patient segmentation and differential response to therapy, cancer genetics
Laboratory of Ronald Evans Studied the role of the nuclear fatty acid receptors PPARg and PPARd in metabolic disease and cancer
Explored the utility of chemically modified antisense oligonucleotides for the treatment of cancer
Modeled tPA purification in Manufacturing Sciences dept